anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The objectives of the proposed study are to advance Type 2 translational science through an effectiveness-implementation "type 2" hybrid design to evaluate the clinical and cost-effectiveness of an efficacious intervention (Teen Marijuana Check-Up, TMCU) and compare the feasibility, acceptability, impact and cost-effectiveness of two integrity monitoring support systems. Marijuana continues to be the most frequently used drug in the U.S. and adolescent use is associated with negative effects such as academic failure, dropout, and emotional problems. Although marijuana is the most common presenting substance for 12-17 year olds seeking substance abuse treatment, few voluntarily seek indicated services. The TMCU is a brief, school-based motivational enhancement therapy approach that has been systematically evaluated in three randomized controlled trials with reliable beneficial effects in prompting voluntary participation in the intervention and decreasing adolescent marijuana use. With TMCU now well-positioned for broad dissemination, its public health impact may be enhanced by further research addressing: 1) to what extent its documented efficacy under controlled conditions translates to real-world effectiveness, and 2) what support systems are most useful in promoting sustained integrity in its delivery by the available school-based personnel. The proposed type 2 effectiveness/implementation hybrid trial will include randomization at multiple levels. Students will be randomly-assigned in a 1:2 ratio to 'services-as-usual' and TMCU intervention conditions, and school-based personnel identified to deliver TMCU will be randomly-assigned to do so under governance of a 'gold-standard' training/oversight support system (i.e., rapid, continual performance-based feedback and weekly coaching about integrity of TMCU delivery) or a less resource-intensive support system similarly including performance-based feedback but with process benchmarking (defined by prior performance of research interventionists in TMCU efficacy trials) prompting points at which these school-based personnel receive purveyor coaching. Expected trial participation of ten schools will enable recruitment of 30 TMCU interventionists, and access to a pool of 250 marijuana-using students during a two-year implementation period. This nested design (e.g., students in schools/intervention conditions; interventionists in schools/training/oversight support systems) will utilize multilevel models in study analyses to account for possible school-level clustering. A cost analysis will also be conducted. Longitudinal outcome and process data will be collected from school based staff (6, 12, 18, \& 24 month follow-ups) and students (3 and 6 month followups).

The trial will occur in Washington state at an opportune time when legislative, fiscal, and socio-cultural factors converge to heighten potential adolescent exposure to marijuana-related harms-represents an effort by this investigative team to respond to such local challenges in a manner that will advance understanding of best practices for dissemination and implementation of this and other efficacious, school-based interventions
Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
Parainfluenza virus (PIV) infections cause considerable morbidity in the immunocompromised population. In the immunocompetent population, PIV is usually self-limited, but can cause more severe disease including pneumonia and tracheobronchitis in adults, and croup and bronchiolitis in young children. DAS181, an inhaled sialidase, cleaves the binding site of PIV from respiratory mucosal cells limiting the ability of PIV to infect new cells. This may improve outcomes in patients with PIV infections.

This exploratory randomized double-blind Phase 2 study will assess the safety and tolerability, and explore the efficacy of DAS181 versus placebo for the treatment of parainfluenza. Thirty eligible patients diagnosed with parainfluenza will be randomized in a 2:1 allocation to receive either DAS181-F02 formulation (10 mg times 5 days) or placebo. Subjects will be followed on Study Days 0, 2, 4, 7, 10, 14, 28, 180, and 365 with a series of clinical, pulmonary function, functional status, virologic, and safety assessments.
Substd. aniline derivs. of formula (I), in which R1 and R2 are H, methyl, CF3 or chloro, are made by reaction of o-chloro benzoic acid with a substd. aniline of formula (II), in inert organic solvent in presence of a catalyst, e.g. copper, its salts or oxides, and a base as acid acceptor, at reflux temp. The corresp. salt is obtd. by treating the acid formed with the appropriate base.
Backgrounds: Idiopathic intracranial hypertension (IIH); symptoms include headaches, blurred vision and papilledema which may lead to permanent visual loss. Definitive diagnosis of IIH usually requires the measurement of intracranial pressure (ICP) via lumbar puncture (LP) which is an invasive technique. In our study, the relationship between ICP and optic nerve sheath diameters (ONSD) were examined. Thus it was investigated whether optic nerve ultrasonography (USG) is a useful tool instead of LP for the diagnosis of IIH.

Methods: A total of 25 patients who applied to the neurology clinics of Ankara Numune Training and Research Hospital between May 2014 and December 2015 and were diagnosed with IIH were included in the study. The control group consisted of 22 individuals who applied with other complaints than headaches. ONSD was measured from both eyes before and after the LP. After pre-LP measurements were taken, opening and closing CSF (cerebrospinal fluid) pressure was measured. In the control group, ONSD was measured with optic USG.
Epoprostenol is rapidly hydrolyzed at neutral pH in blood and is also subject to enzymatic degradation. Animal studies using tritium-labeled epoprostenol have indicated a high clearance (93 mL/kg/min), small volume of distribution (357 mL/kg), and a short half-life (2.7 minutes). During infusions in animals, steady-state plasma concentrations of tritium-labeled epoprostenol were reached within 15 minutes and were proportional to infusion rates.

No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol. The in vitro half-life of epoprostenol in human blood at 37°C and pH 7.4 is approximately 6 minutes; therefore, the in vivo half-life of epoprostenol in humans is expected to be no greater than 6 minutes. The in vitro pharmacologic half-life of epoprostenol in human plasma, based on inhibition of platelet aggregation, was similar for males (n=954) and females (n=1,024).

Tritium-labeled epoprostenol has been administered to humans in order to identify the metabolic products of epoprostenol. Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. The recovery of radioactivity in urine and feces over a 1-week period was 82% and 4% of the administered dose, respectively. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.
Participants will receive the RP2D of mirdametinib. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
INTRODUCTION: Pediatric urolithiasis is a less common disease with a steadily increasing incidence of 10.6 % per year. The comprehensive management of pediatric urolithiasis is more challenging than in adults, and published studies of endourological treatment in children have small sample sizes and older mean ages, which may not be representative of the overall pediatric population, especially in infants and toddlers. This study aimed to report results of retrograde ureteroscopy for treating pediatric ureteral stones in infants and toddlers (<3 years) from a single center in China.
METHODS: Demographic and surgical data of infants and toddlers with ureteral stones who underwent retrograde URS were retrospectively analyzed from January 2015 to September 2022.
RESULTS: The mean age of 100 infants (73 boys and 27 girls) was 19.6 ± 7.6 months and stone burden was 0.27 (0.11-0.52) cm³. 111 procedures were performed for all children due to 11 patients with bilateral ureteric stones were simultaneously treated. Among them, 70.3 % were semi-rigid URS, 12.6 % were Micro-URS and 17.1 % were flexible URS. SFR was up to 96 %, the median operation time and hospitalization days were 35.0 (25.0-50.0) minutes and 6.0 (5.0-6.0) days, respectively. 15 (15.0 %) infants had postoperative fever (Grade I), and complications above grade I were not observed.
DISCUSSIONS: This research reported the largest sample size of infant and toddler ureteric stones (under 3 years old) and shared optimal management strategies for these special populations. Compared to other related studies, we had a higher SFR due to diverse management strategies and reasonable application of pre-operative ureteric stents. The most important potential reason why our complication rate was relatively higher might be the younger population under 3 years old. In additionally, the reason of long hospitalization was maybe some patients underwent staged surgeries during one hospitalization. Those results indicated the robust effectiveness of URS for infants. This study has limitations, including its retrospective single-center design, absence of long-term follow-up data, and potential variability in surgical outcomes due to differences in surgeons' experience.
CONCLUSIONS: The experience of endourologic procedures for 100 infant and toddler patients with ureteric stones from a Chinese single center was reported. And URS showed its effectiveness and safety for those special populations based on its high SFR and low complication rate.
Control group will perform flexibility exercises for the hip (flexors and adductors), knee (flexors and extensors), and calf muscle, with a hold of 15 sec ,5 repetitions. Strengthening exercises for core muscles (curl-ups, prone extension),hip extensors (in prone position), hamstrings, quadriceps (knee extension in high sitting).Walking in all directions, standing on rough and soft surfaces, stepping down and up, walking,standing on one limb with both eyes closed and open. Each session will start with a 5-minute warm-up and 5-minute cool-down, session duration 45 minutes,3 times a week.
Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
Dose escalation and expansion of ZVS101e. All patients enrolled in the study will receive a single subretinal injection of ZVS101e in one eye.
A visual aid comparison system applied in a medical institution is suitable for identifying a target user in the medical institution and comprises an image unit suitable for capturing a plurality of images containing a plurality of character areas, an operation unit, and a servo unit. The operation unit generates a plurality of comprehensive scores corresponding to the character areas, generates a sorting result according to the magnitude of the comprehensive scores, and selects at least one character area as at least one candidate character area. The servo unit selects an associated image related to the at least one candidate character area from a plurality of standard facial data according to the sorting results of the images, and selects one identity data to be confirmed related to the associated image from a plurality of identity data. The present invention also provides a method executed by the aforementioned system. The visual aid comparison system applied in the medical institution further comprises a base unit adapted to be mounted in the medical institution. The image unit is mounted on the base unit and includes an imaging module suitable for capturing a plurality of images containing a plurality of character areas. One of the character areas is the target user. The operation unit is connected to the image unit by information, and includes a calculation module for generating a plurality of comprehensive scores corresponding to the corresponding character areas according to the evaluation data, and a processing module connected to the calculation module by information.
<P>PROBLEM TO BE SOLVED: To provide CysLT2 and new applications of its ligand.  <P>SOLUTION: The present invention provides a method for controlling apoptosis by CysLT2 and its ligand. The method is useful for biological research involving treatment of diseases and creation of medicines, etc. The present invention provides a medicinal composition for preventing or treating diseases related to apoptosis, containing CysLT2 ligand as an active ingredient. The present invention provides a method for screening substances for controlling apoptosis and therapeutic medicines for apoptosis-related diseases by using CsysLT2, a gene encoding the CysLT2 and CysLT2 ligand. The present invention further provides CysLT2 of guinea pig and a human embryonal kidney HEK293 cell stably expressing the CysLT2.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PURPOSE: To prepare a therapeutic agent having the same homeopathy as that of a raw material without possessing the toxicity or pathologenicity present in the raw material by introducing a homeopathic first mother liquor into a composite mammary gland tissue of ungulates and taking out the second mother liquor from the tissue. CONSTITUTION: A (non)toxic or a (non)pathologic raw material is selected and an excipient without having irritation to a tissue (e.g. a physiological saline, distilled water or a purified whey) is used to prepare a solution and produce the first homeopathic mother liquor. The resultant mother liquor is then introduced into a composite mammary gland tissue of ungulates (preferably cattle) and the raw material solution is subsequently converted to the second mother liquor having characteristics of a sarcode and the homeopathy of the first mother liquor. The second mother liquor is taken out of the tissue and large molecules, containing an antibody and having >=0.2μm size are separated from the mother liquor and continuously diluted to 10<3> to 10<30> times. Thereby, the homeopathic product having <2,000 molecular weight is obtained.
A method for managing glucose levels of a patient under the supervision of a healthcare professional (HCP). The method includes obtaining patient information for the patient, the patient information comprising patient medication data, patient monitoring data, and patient characteristic data. The method also includes creating a patient risk profile based on the patient information. The method also includes determining a likelihood that the patient will experience hyperglycemic effects based on the patient risk profile. The method also includes determining an optimum treatment plan for the patient based on the patient risk profile and the likelihood that the patient will experience hyperglycemic effects. The method also includes executing the optimum treatment plan.
The invention relates to a synthesis method and application of a manganese-based magnetic resonance imaging contrast agent with high relaxation rate. The method comprises the steps of firstly reducing a small amount of potassium permanganate by using bovine serum albumin (the mass ratio is 75:1) to obtain an albumin-manganese precursor BM with low manganese content (0.34%), and then adding ethanol to the precursor BM to desolvate and crosslink BM by glutaraldehyde to synthesize the albumin-manganese crosslinked body C-BM. Albumin-manganese Cross-linking T  1  The relaxation rate is improved by 12.2 times, so that the T of BM  1  Relaxation rate was from 5.49mM  ‑1  s  ‑1  (0.5T) up to 67.2mM of C-BM  ‑1  s  ‑1  (0.5T). At the same Mn concentration, the MRI brightness of the C-BM solution was significantly better than that of the BM solution, and the MRI signal enhancement (%) was 8.7 times that of BM. Human lung cancer cell H460 subcutaneous tumor-bearing mice are injected with C-BM to obtain high contrast T at tumor  1  The MRI signal enhancement (%) of the weighted magnetic resonance image is 2.6 times that of BM. T synthesized by the invention  1  Contrast agent C-BM at T  1  The weighted magnetic resonance imaging has important application prospect。
In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
Patients should be counseled that antibacterial drugs including lincomycin injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When lincomycin injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by lincomycin injection or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibacterial which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with an antibacterial, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after taking the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.
BACKGROUND: Chronic kidney disease (CKD) is a global health problem with rising prevalence, morbidity, mortality, and associated costs. Early identification and risk stratification are key to preventing progression to kidney failure. However, there is a paucity of data on practice patterns of kidney function assessment to guide the development of improvement strategies, particularly in lower-income countries.
METHODS: A retrospective observational analysis was conducted in a nationwide laboratory database in Brazil. We included all adult patients with at least one serum creatinine assessment between June 2018 and May 2021. Our primary objective was to determine the proportion of patients with estimated glomerular filtration rate (eGFR) evaluations accompanied by predicted levels of urinary albumin-to-creatinine ratio (pACR) assessments within 12 months.
RESULTS: Out of 4,5323,332 serum creatinine measurements, 42% lacked pACR measurements within 12 months. Approximately 10.8% of tests suggested CKD, mostly at stage 3a. The proportion of serum creatinine exams paired with pACR assessment varied according to the CKD stage. Internal Medicine, Cardiology, and Obstetrics/Gynecology were the specialties requesting most of the creatinine tests. Nephrology contributed with only 1.1% of serum creatinine requests for testing.
CONCLUSION: Our findings reveal that a significant proportion of individuals with a creatinine test lack an accompanying urinary albuminuria measurement in Brazil, contrary to the recommendations of the international guidelines. Non-Nephrologists perform most kidney function evaluations, even among patients with presumable advanced CKD. This highlights the urge to incorporate in clinical practice the early detection of CKD and to encourage more collaborative multidisciplinary care to improve CKD management.
PURPOSE: The present invention provides a preparation for injection containing a lipid A analog and a process for preparing the same. A preparation for injection prepared by dissolving a lipid A analog or a pharmacologically acceptable salt thereof in an alkaline aqueous solution, at an elevated temperature if necessary, and then adding a buffer thereto, and a process for preparing the same. CONSTITUTION: A preparation for injection prepared by dissolving a lipid A analog or a pharmacologically acceptable salt thereof in an alkaline solution and subsequently adding a buffer thereto. The alkaline aqueous solution is a temperature-elevated alkaline aqueous solution. The temperature of the temperature-elevated alkaline aqueous solution is elevated to the phase transition temperature of the lipid A analog or pharmacologically acceptable salt thereof or higher. The buffer has a pH of 4 to 9 and containing a saccharide.
Children with chronic idiopathic thrombocytopenic purpura who have Helicobacter pylori infection are enrolled. Helicobacter pylori infection is diagnosed by urea breath test. Patients who have Helicobacter pylori infection will be randomized into 2 groups: control and treatment groups. The treatment group will receive 2 antibiotics and proton-pump inhibitors for 14 days for eradication of infection. Repeated urea breath test at week 6-8 after treatment. Blood tests for platelet count will be performed every month for 6 months in both groups. Platelet count at 6 months in both group will be compared.Blood for platelet antibody will be performed at 3 and 6 months. Control group will receive treatment for Helicobacter pylori at the end of the study.